Mi Ran Yun

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of <i>EGFR</i> Exon 20 Insertion–Driven NSCLC

Jiyeon Yun, Soo‐Hwan Lee, Seok‐Young Kim et al. · Cancer Discovery · 2020 · 272 citations · Full text

Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma

Seok‐Young Kim, Sang-Min Kim, Su-Min Lim et al. · Clinical Cancer Research · 2021 · 143 citations · Full text

YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non–Small Cell Lung Cancer

Jiyeon Yun, Min Hee Hong, Seok‐Young Kim et al. · Clinical Cancer Research · 2019 · 124 citations · Full text

Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer

Mi Ran Yun, Dong Hwi Kim, Seok‐Young Kim et al. · Clinical Cancer Research · 2020 · 115 citations · Full text

Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition

Hyo Song Kim, Minkyu Jung, Hari Kang et al. · Oncogene · 2017 · 93 citations · Full text

Medicine, Receptor Tyrosine Kinase, Melanoma +9